Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial.

PubWeight™: 3.81‹?› | Rank: Top 1%

🔗 View Article (PMID 18849193)

Published in Lancet Neurol on October 10, 2008

Authors

Mats Engström1, Thomas Berg, Anna Stjernquist-Desatnik, Sara Axelsson, Anne Pitkäranta, Malou Hultcrantz, Mervi Kanerva, Per Hanner, Lars Jonsson

Author Affiliations

1: Department of Otorhinolaryngology and Head and Neck Surgery, Uppsala University Hospital, Uppsala, Sweden. mats.engstrom@akademiska.se

Associated clinical trials:

Scandinavian Bell's Palsy Study (SBPS) | NCT00510263

Articles citing this

The benefits of steroids versus steroids plus antivirals for treatment of Bell's palsy: a meta-analysis. BMJ (2009) 1.77

Bell's palsy: new evidence provides a definitive drug therapy strategy. Br J Gen Pract (2009) 1.38

Treatment of Bell's palsy--the pendulum has swung back to steroids alone. Lancet Neurol (2008) 1.08

The neurologist's dilemma: a comprehensive clinical review of Bell's palsy, with emphasis on current management trends. Med Sci Monit (2014) 0.99

Corticosteroid and antiviral therapy for Bell's palsy: a network meta-analysis. BMC Neurol (2011) 0.99

Prognostication of recovery time after acute peripheral facial palsy: a prospective cohort study. BMJ Open (2013) 0.89

Bell's palsy: Treatment guidelines. Ann Indian Acad Neurol (2011) 0.88

Impact of clinical trial findings on Bell's palsy management in general practice in the UK 2001-2012: interrupted time series regression analysis. BMJ Open (2013) 0.85

Is antiviral medication for severe Bell's palsy still useful? Lancet Neurol (2009) 0.83

Clinical characteristics and cerebrospinal fluid parameters in patients with peripheral facial palsy caused by Lyme neuroborreliosis compared with facial palsy of unknown origin (Bell's palsy). BMC Infect Dis (2011) 0.82

Prednisolone--but not antiviral drugs--improves outcome in patients with Bell's palsy. Nat Clin Pract Neurol (2009) 0.80

Bell's palsy: symptoms preceding and accompanying the facial paresis. ScientificWorldJournal (2014) 0.80

Evaluation of the early phase of Bell's palsy using 3 T MRI. Eur Arch Otorhinolaryngol (2011) 0.79

Bell's palsy in pregnancy: underlying HELLP syndrome or pre-eclampsia? Obstet Med (2013) 0.79

Is There a Relationship Between Bell's Palsy and Internal Auditory Canal? Indian J Otolaryngol Head Neck Surg (2014) 0.77

Clinical pearls in infectious diseases. Mayo Clin Proc (2011) 0.77

Prednisolone and acupuncture in Bell's palsy: study protocol for a randomized, controlled trial. Trials (2011) 0.77

Modern management of facial palsy: a review of current literature. Br J Gen Pract (2013) 0.77

Acupuncture for the sequelae of Bell's palsy: a randomized controlled trial. Trials (2015) 0.76

Facial Palsy, a Disorder Belonging to Influential Neurological Dynasty: Review of Literature. N Am J Med Sci (2016) 0.75

Effects of electroacupuncture therapy for Bell's palsy from acute stage: study protocol for a randomized controlled trial. Trials (2015) 0.75

Reactivation of type 1 herpes simplex virus and varicella zoster virus in an immunosuppressed patient with acute peripheral facial weakness. J Neurol Sci (2011) 0.75

ACP Journal Club. Prednisolone, but not valacyclovir, reduced time to complete recovery of facial-nerve function in Bell palsy. Ann Intern Med (2009) 0.75

Single dose intravenous methyl prednisolone versus oral prednisolone in Bell's palsy: a randomized controlled trial. Indian J Pharmacol (2015) 0.75

Bell's Palsy in Children (BellPIC): protocol for a multicentre, placebo-controlled randomized trial. BMC Pediatr (2017) 0.75

Peripheral facial nerve palsy after therapeutic endoscopy. Clin Endosc (2015) 0.75

Treatment of Bell's Palsy Using Monochromatic Infrared Energy: A Report of 2 Cases. J Chiropr Med (2014) 0.75

Bell's palsy. BMJ Clin Evid (2014) 0.75

Role of Kabat rehabilitation in facial nerve palsy: a randomised study on severe cases of Bell's palsy. Acta Otorhinolaryngol Ital (2016) 0.75

Increased seroprevalence of Toxoplasma gondii in a population of patients with Bell's palsy: a sceptical interpretation of the results regarding the pathogenesis of facial nerve palsy. Eur Arch Otorhinolaryngol (2011) 0.75

A young woman with acute one-sided facial paralysis. CMAJ (2016) 0.75

Peripheral neuropathies: corticosteroids and antivirals in Bell palsy. Nat Rev Neurol (2013) 0.75

Steroid-antivirals treatment versus steroids alone for the treatment of Bell's palsy: a meta-analysis. Int J Clin Exp Med (2015) 0.75

Bell's palsy. BMJ Clin Evid (2011) 0.75

Comparison of acyclovir and famciclovir for the treatment of Bell's palsy. Eur Arch Otorhinolaryngol (2016) 0.75

Automated and objective action coding of facial expressions in patients with acute facial palsy. Eur Arch Otorhinolaryngol (2014) 0.75

Facial palsy following cochlear implantation. Eur Arch Otorhinolaryngol (2016) 0.75

Articles by these authors

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31

Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med (2007) 5.13

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology (2004) 3.70

Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol (2004) 3.56

Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology (2006) 3.18

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13

Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology (2010) 3.02

Slow initial β-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infect Dis (2011) 2.90

Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest (2010) 2.87

Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology (2006) 2.68

Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet (2007) 2.48

Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology (2012) 2.42

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology (2005) 2.19

Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med (2012) 2.14

Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology (2013) 2.13

Polymorphisms in melanoma differentiation-associated gene 5 link protein function to clearance of hepatitis C virus. Hepatology (2015) 2.11

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol (2010) 2.09

Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology (2008) 2.03

First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum Mol Genet (2008) 1.98

Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl (2011) 1.92

A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nat Genet (2006) 1.90

Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut (2012) 1.86

Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology (2002) 1.85

Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology (2010) 1.79

Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology (2007) 1.79

Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology (2009) 1.79

Omega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines. Hepatology (2007) 1.73

Assistance of microbial glycolipid antigen processing by CD1e. Science (2005) 1.73

Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology (2011) 1.71

Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology (2011) 1.70

Human rhinovirus in bronchial epithelium of infants with recurrent respiratory symptoms. J Allergy Clin Immunol (2006) 1.68

Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS (2006) 1.68

The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol (2008) 1.65

Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology (2010) 1.65

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol (2010) 1.63

Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology (2011) 1.62

Reactivation of viral replication after replacement of tenofovir by adefovir. Hepatology (2005) 1.60

Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis (2013) 1.58

Production of pluripotent stem cells by oocyte-assisted reprogramming: joint statement with signatories. Natl Cathol Bioeth Q (2005) 1.57

Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis. Liver Int (2011) 1.57

Pregnancy in primary sclerosing cholangitis. Gut (2011) 1.55

Is it possible to diagnose acute otitis media accurately in primary health care? Fam Pract (2003) 1.55

Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection. J Clin Gastroenterol (2012) 1.53

Antimicrobial resistance in urinary pathogens among Swedish nursing home residents remains low: a cross-sectional study comparing antimicrobial resistance from 2003 to 2012. BMC Geriatr (2014) 1.52

Distinct, alcohol-modulated effects of PNPLA3 genotype on progression of chronic hepatitis C. J Hepatol (2011) 1.52

Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol (2005) 1.49

Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology (2009) 1.47

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology (2005) 1.45

Viscoelasticity-based staging of hepatic fibrosis with multifrequency MR elastography. Radiology (2010) 1.45

Prognostic accuracy of five simple scales in childhood bacterial meningitis. Scand J Infect Dis (2012) 1.44

Efficacy and safety of orbital decompression in treatment of thyroid-associated ophthalmopathy: long-term follow-up of 78 patients. Clin Endocrinol (Oxf) (2007) 1.44

The effect of study design and analysis methods on recovery rates in Bell's palsy. Laryngoscope (2009) 1.42

Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol (2011) 1.36

IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med (2011) 1.36

Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol (2012) 1.35

Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation (2004) 1.33

Outcome of treatment with valacyclovir and prednisone in patients with Bell's palsy. Ann Otol Rhinol Laryngol (2003) 1.29

Human picornavirus and coronavirus RNA in nasopharynx of children without concurrent respiratory symptoms. J Med Virol (2002) 1.28

A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. J Hepatol (2007) 1.27

Computational methods for the design of effective therapies against drug resistant HIV strains. Bioinformatics (2005) 1.27

Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridization. J Transl Med (2011) 1.27

Exposure to environmental tobacco smoke and health effects among hospitality workers in Sweden--before and after the implementation of a smoke-free law. Scand J Work Environ Health (2008) 1.25

Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: coexpression with vascular endothelial growth factor-A predicts poor survival. Cancer (2011) 1.24

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology (2010) 1.24

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther (2011) 1.22

Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med (2011) 1.19

Estrogen receptor beta protects against acoustic trauma in mice. J Clin Invest (2008) 1.16

Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. Hepatology (2010) 1.15

The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS One (2011) 1.13

Presence of specific viruses in the middle ear fluids and respiratory secretions of young children with acute otitis media. J Med Virol (2004) 1.12

Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology (2002) 1.11

Differential priming of CD8 and CD4 T-cells in animal models of autoimmune hepatitis and cholangitis. Hepatology (2007) 1.10

Serotypes of Streptococcus pneumoniae isolated from blood and cerebrospinal fluid related to vaccine serotypes and to clinical characteristics. Scand J Infect Dis (2006) 1.08

Microbiologic findings in acute facial palsy in children. Otol Neurotol (2013) 1.08

Hepcidin as a predictor of treatment response in chronic hepatitis C infection. Hepatology (2014) 1.08

Viral etiology of frequently recurring respiratory tract infections in children. Clin Infect Dis (2002) 1.08

Agreement between the Sunnybrook, House-Brackmann, and Yanagihara facial nerve grading systems in Bell's palsy. Otol Neurotol (2004) 1.08

Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. Trends Mol Med (2010) 1.07

MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. PLoS One (2012) 1.07

The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. J Hepatol (2007) 1.06

A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J Hepatol (2008) 1.05

A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. PLoS One (2012) 1.05

Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood (2002) 1.05

Sunnybrook and House-Brackmann Facial Grading Systems: intrarater repeatability and interrater agreement. Otolaryngol Head Neck Surg (2006) 1.04

Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection. J Hepatol (2004) 1.04

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol (2017) 1.04

Risk factors for death and severe neurological sequelae in childhood bacterial meningitis in sub-Saharan Africa. Clin Infect Dis (2009) 1.02

Acoustic radiation force impulse imaging (ARFI) for non-invasive detection of liver fibrosis: examination standards and evaluation of interlobe differences in healthy subjects and chronic liver disease. Scand J Gastroenterol (2011) 1.01

Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. Gastroenterology (2003) 1.00

The toll-like receptor 2 (TLR2) -196 to -174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. Int J Cancer (2011) 1.00

Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients. J Virol (2013) 1.00

Management of chronic hepatitis B: status and challenges beyond treatment guidelines. Semin Liver Dis (2010) 0.98

Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C. Hepatology (2004) 0.98

HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge. Intervirology (2012) 0.97

Association of CTLA4 single nucleotide polymorphisms with viral but not autoimmune liver disease. Eur J Gastroenterol Hepatol (2007) 0.97

Evaluation of a physiotherapeutic treatment intervention in "Bell's" facial palsy. Physiother Theory Pract (2006) 0.97